28 September 2024 in Developmental Medicine & Child Neurology
Aim: To find proof‐of‐principle evidence for short‐term treatment with lamotrigine to improve cognitive functioning of adolescents with neurofibromatosis type 1 (NF1).Method: This was a double‐blind, parallel‐group, randomized, placebo‐controlled clinical trial (the NF1‐EXCEL trial: Examining the Cognitive and Electrophysiological benefit of Lamotrigine in Neurofibromatosis type 1; Clinicaltrials.gov identifier NCT02256124), with the aim of enrolling 60 adolescents with NF1 aged 12 to 17 years 6 months. The short‐term study intervention was 200 mg of lamotrigine taken orally for 26 weeks. The primary outcome was performance IQ tested with the Wechsler Intelligence Scale for Children, Third Edition, complemented with secondary outcomes for visuospatial learning efficacy, visual perception, visual sustained attention, fine motor coordination, attention‐deficit/hyperactivity problems, and executive functioning.Results: We screened 402 adolescents with NF1, of whom 31 (eight females) entered the study. Complete‐case analysis showed no effect of lamotrigine on either performance IQ (−0.23, 95% CI −6.90 to 6.44) or most secondary outcomes. Visual sustained attention showed a trend towards better performance in the lamotrigine group (−0.81, 95% CI −1.67 to 0.04).Interpretation: Lamotrigine did not improve cognitive functioning in adolescents with NF1. The small treatment effects make it unlikely that a larger sample size could have changed this conclusion.
12 May 2021 in Journal of Attention Disorders
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that is associated with cognitive disabilities, including attention and motor learning problems. These disabilities have been extensively studied in children with NF1 but limited studies have been performed in adults. Attention, motor learning and intellectual performance were studied with neuropsychological tasks in 32 adults with NF1 and 32 controls. The NF1 and control group performed similarly on attention and motor learning tasks, although controls had shorter reaction times than adults with NF1 during the motor learning task (t[60] = −2.20, p = .03). Measures of attention or motor learning were not significantly associated with reduced intellectual performance in NF1. In contrast to many studies in children with NF1, our findings did not provide evidence for presence of attention or motor learning problems in adults with NF1 in neuropsychological tasks. Our observations may be of clinical importance to determine treatment focus in adults with NF1.
9 January 2023 in Journal of Intellectual Disability Research
Background: Neurofibromatosis type 1 (NF1) is a neurodevelopmental genetic disorder associated with visual–spatial and visuomotor deficits, which have not been studied well in adults with NF1.Methods: In 22 adults with NF1 and 31 controls, visuomotor functioning was assessed by measuring eye latency, hand latency and hand accuracy during visuomotor tasks. Visual–spatial functioning was assessed by measuring eye movement responses during the Visual Threshold Task.Results: The NF1 group had a significantly shorter eye latency than the control group and was less accurate in their hand movements during specific visuomotor tasks. The groups showed no differences in eye movement responses during the Visual Threshold Task and in hand latency during the visuomotor tasks.Conclusions: In contrast to studies in children with NF1, we found no alterations in visual–spatial information processing in adults. Impairments in eye latency and hand accuracy during specific visuomotor tasks may indicate deficits in visuomotor functioning in adults with NF1.